Literature DB >> 32297825

Modified Goldilocks Design with strict type I error control in confirmatory clinical trials.

Tianyu Zhan1, Hongtao Zhang2, Alan Hartford3, Saurabh Mukhopadhyay1.   

Abstract

Goldilocks Design (GD) utilizes predictive probability to adaptively select a trial's sample size based on accumulating data. In order to control type I error at a desired level for a subset of the null space, extensive simulations at the study design stage are required to choose critical values, which is a challenge for this type of Bayesian adaptive design to be used for confirmatory trials. In this article, we propose a Modified Goldilocks Design (MGD) where type I error is analytically controlled over the entire null space. We do so by applying the conditional invariance principle and a combination test approach on [Formula: see text]-values that are obtained from independent cohorts of subjects. Simulation studies show that despite analytic control of type I error rate, the proposed MGD has similar power when compared with the original GD. We further apply it to an example trial with time-to-event endpoint in oncology.

Entities:  

Keywords:  Bayesian adaptive design; combination test approach; sample size selection

Mesh:

Year:  2020        PMID: 32297825     DOI: 10.1080/10543406.2020.1744620

Source DB:  PubMed          Journal:  J Biopharm Stat        ISSN: 1054-3406            Impact factor:   1.051


  1 in total

1.  Deep historical borrowing framework to prospectively and simultaneously synthesize control information in confirmatory clinical trials with multiple endpoints.

Authors:  Tianyu Zhan; Yiwang Zhou; Ziqian Geng; Yihua Gu; Jian Kang; Li Wang; Xiaohong Huang; Elizabeth H Slate
Journal:  J Biopharm Stat       Date:  2021-10-10       Impact factor: 1.503

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.